Black Diamond Therapeutics (NASDAQ:BDTX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Black Diamond Therapeutics (NASDAQ:BDTX) announced its quarterly earnings results on Thursday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03, Zacks reports.

Black Diamond Therapeutics Stock Performance

BDTX stock traded up $0.04 during mid-day trading on Thursday, hitting $1.90. 196,540 shares of the company were exchanged, compared to its average volume of 811,365. Black Diamond Therapeutics has a 1-year low of $1.77 and a 1-year high of $7.66. The firm’s 50 day simple moving average is $2.25 and its 200 day simple moving average is $3.24. The firm has a market cap of $107.51 million, a P/E ratio of -1.43 and a beta of 2.52.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday, November 6th.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.